Format

Send to

Choose Destination
BMC Biotechnol. 2019 Feb 18;19(1):14. doi: 10.1186/s12896-019-0504-z.

Ex vivo evolution of human antibodies by CRISPR-X: from a naive B cell repertoire to affinity matured antibodies.

Author information

1
CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
2
LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France.
3
Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France.
4
HLA Laboratory, EFS Centre Pays de la Loire, Nantes, France.
5
CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France. Richard.Breathnach@univ-nantes.fr.
6
LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France. Richard.Breathnach@univ-nantes.fr.
7
CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France. xavier.saulquin@univ-nantes.fr.
8
LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France. xavier.saulquin@univ-nantes.fr.

KEYWORDS:

AID; CRISPR; CRISPR-X; Cytofluorimetry; HLA; Human antibodies; SHM; Tetramers

PMID:
30777060
PMCID:
PMC6378725
DOI:
10.1186/s12896-019-0504-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center